Elite Pharmaceuticals (ELTP) Research & Development (2010 - 2026)
Elite Pharmaceuticals (ELTP) recorded Research & Development of $2.03 million in fiscal Q1 2027 (quarter ended Jun 30, 2026), up 21.3% from $1.67 million a year earlier and up 23.8% from the prior quarter.
Elite Pharmaceuticals (ELTP) Research & Development (2010 - 2026) Analysis & Trends
On a TTM basis, Elite Pharmaceuticals' Research & Development came in at $6.1 million as of Jun 30, 2026, down 18.4% year-over-year; for FY2026 (ended Mar 31, 2026), it came in at $5.74 million, down 27.9% from FY2025.
- Annual Research & Development has a five-year compound annual growth rate of 2.4% (FY2021 to FY2026).
- Across earlier fiscal years, Research & Development came in at $7.96 million in FY2025 (+15.7%), $6.88 million in FY2024 (+11.0%), $6.2 million in FY2023 (+53.0%) and $4.05 million in FY2022 (-20.8%).
- The fiscal Q1 2027 figure is the highest quarterly Research & Development since fiscal Q4 2025.
- On a year-over-year basis, Research & Development rose in three of the last eight quarters, with an average decline of 8.8%.
- Peak year-over-year performance for Research & Development in the last five years was growth of 228.2% in fiscal Q4 2023, against a decline of 58.4% in fiscal Q4 2022 at the low end.
- Per Business Quant, the preceding three fiscal quarters came in at $1.64 million (Q4 2026), $1.04 million (Q3 2026) and $1.39 million (Q2 2026).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,146.94 Bn | 1,115.53 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 624.96 Bn | 543.49 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 510.15 Bn | 483.27 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 366.13 Bn | 320.51 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 297.75 Bn | 261.74 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.93 Bn | 235.62 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 236.51 Bn | 191.91 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 194.27 Bn | 168.47 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 171.74 Bn | 118.39 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Elite Pharmaceuticals | 258.43 Mn | 140.10 Mn | 13.51 Mn | 2.03 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.03 Mn |
| Mar 31, 2026 | 1.64 Mn |
| Dec 31, 2025 | 1.04 Mn |
| Sep 30, 2025 | 1.39 Mn |
| Jun 30, 2025 | 1.67 Mn |
| Mar 31, 2025 | 2.04 Mn |
| Dec 31, 2024 | 1.79 Mn |
| Sep 30, 2024 | 1.97 Mn |
| Jun 30, 2024 | 2.16 Mn |
| Mar 31, 2024 | 1.72 Mn |
| Dec 31, 2023 | 1.40 Mn |
| Sep 30, 2023 | 2.62 Mn |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2023 | 2.43 Mn |
| Dec 31, 2022 | 1.44 Mn |
| Sep 30, 2022 | 1.23 Mn |
| Jun 30, 2022 | 955,443.00 |
| Mar 31, 2022 | 738,809.00 |
| Dec 31, 2021 | 956,628.00 |
| Sep 30, 2021 | 1.12 Mn |
Elite Pharmaceuticals Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=ELTP&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "ELTP", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=ELTP&period=max&api_key=YOUR_API_KEY");
const data = await res.json();